Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Albert David Limited (ALBERTDAVD.NS)
Kolkata, IN
Albert David Limited is an Indian pharmaceutical company specializing in the production and distribution of a diverse array of medical products. Its offerings encompass pharmaceutical formulations, intravenous solutions, herbal medicines, bulk drug substances, and disposable medical devices like syringes and needles. The company's formulations address various therapeutic areas, including injectable medications (parenterals), oral and enteral drugs, topical applications, and vision care products. In addition to its operations within India, Albert David Limited actively exports its products to markets across Latin America, Southeast Asia, and different African nations. The company, established in 1938, is headquartered in Kolkata, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.57% | -7.92% | +0.68% | -1.67% | -11.40% | -1.98% | -12.73% | +20.88% | +64.22% | +131.22% | +131.22% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-3.5% Q1'26: +14.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-108.7% Q1'26: -107.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-7.2% Q1'26: -31.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-1.3% Q1'26: +0.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-1.6% Q1'26: +0.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.43× ★ Q1'26: 2.69× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2020 actual |
Mar 2021 actual |
Mar 2024 actual |
Mar 2025 actual |
|---|---|---|---|---|
| Revenue |
3.18B
est: 3.39B (-6.1%)
|
2.46B
est: 3.73B (-33.9%)
|
3.60B
est: 3.34B (+7.9%)
|
3.46B
est: 3.67B (-5.9%)
|
| EBITDA |
376.14M
est: 545.07M (-31.0%)
|
364.59M
est: 587.76M (-38.0%)
|
1.05B
est: 537.02M (+94.7%)
|
30.26M
est: 590.72M (-94.9%)
|
| EBIT |
295.91M
est: 459.83M (-35.6%)
|
282.28M
est: 495.84M (-43.1%)
|
974.93M
est: 453.03M (+115.2%)
|
-39.43M
est: 498.33M (-107.9%)
|
| Net Income |
191.69M
est: 303.69M (-36.9%)
|
221.43M
est: 342.86M (-35.4%)
|
754.20M
est: 297.73M (+153.3%)
|
172.01M
est: 337.68M (-49.1%)
|
| SGA |
610.91M
est: 790.41M (-22.7%)
|
400.67M
est: 852.32M (-53.0%)
|
1.01B
est: 778.73M (+29.3%)
|
1.26B
est: 856.60M (+47.2%)
|
| EPS |
33.59
est: 53.21 (-36.9%)
|
38.80
est: 60.37 (-35.7%)
|
132.15
est: 52.17 (+153.3%)
|
30.14
est: 59.19 (-49.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Arun Kumar Kothari | Executive Chairman | 25M | male |
| Anil Kumar Semwal | Head of QA (Contract Manufacturing) | — | male |
| Chandra Thakur | Head of Operations - Ghaziabad Plant | — | male |
| Kuntal Ganguly | Head of R&D | — | — |
| Lalit Lohia | Company Secretary, Compliance Officer & Chief Investor Relations Officer | — | male |
| Ranadeep Bhattacharya | Chief Financial Officer | — | male |
| Santanu Bhattacharya | Plant Head - Kolkata | — | male |
| Santosh Kumar Dubey | Divisional Head of Sunrise | — | male |
| Adi Joyti Chattopadhyay | Corporate Head of Human Resource | — | male |
| Siddhesh Subhash Rege | Head of Sales Training | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALBERTDAVD.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
